1570Low rates of virologic failure among previously unmonitored patients in Malawi
نویسندگان
چکیده
in Malawi Sarah E. Rutstein; Mina Hosseinipour MD, MPH; Alice Soko; Memory Mkandawire; Eva Stein; Charles Mclendon; Deborah Kamwendo; Mary Kadiwa; Eldee Paladar; Abdoulaye Sarr; Sundeep Gupta MD, MPH; Frank Chimbwandira; Reuben Mwenda; Ronald Mataya, MD; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC; University of North Carolina Project, Lilongwe, Malawi; Laboratory Capacity Consortium, Lilongwe, Malawi; Centers for Disease Control and Prevention Malawi, Lilongwe, Malawi; Centers for Disease Control and Prevention, Atlanta, GA; Malawi Ministry of Health, Lilongwe, Malawi; School of Public Health, Loma Linda University, Loma Linda, CA
منابع مشابه
Using administrative claims data to estimate virologic failure rates among human immunodeficiency virus-infected patients with antiretroviral regimen switches.
OBJECTIVE To develop and validate a claims signature model that estimates proportions of HIV-infected patients in administrative claims databases who switched combination antiretroviral therapy (cART) regimens because of virologic failure. METHODS The authors used an HIV-specific registry (development data set) to develop logistic regression models to estimate odds of virologic failure among ...
متن کاملABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection. We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients ...
متن کاملMarginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa
BACKGROUND South African HIV treatment guidelines call for patients who fail first-line antiretroviral therapy (ART) to be switched to second-line ART, yet logistical issues, clinician decisions and patient preferences make delay in switching to second-line likely. We explore the impact of delaying second-line ART after first-line treatment failure on rates of death and virologic failure. MET...
متن کاملPharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
BACKGROUND Among HIV-1 infected patients who achieved virologic suppression, the use of atazanavir without pharmacologic boosting is debated. We evaluated the efficacy and tolerance of maintenance therapy with unboosted atazanavir in clinical practice. METHODS AND RESULTS This multicenter retrospective cohort study evaluated the efficacy of switching HIV-1-infected patients controlled on trip...
متن کاملDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3. METHODS In this open-label study, we initially randomly assigned 44 previously untreated pa...
متن کامل